Soma Pharmacy Blognews

NSAIDs No Buffer to Skin Cancer (CME/CE) Nonsteroidal anti-inflammatory drugs (NSAIDs) offer no protection against skin cancer, investigators have concluded from reviewing records of a large patient cohort.

Botox May Have Migraine Potential (CME/CE) Botulinum toxin type A (Botox) provided significant relief from certain types of migraine in a small clinical study of migraine patients undergoing cosmetic procedures of the upper face.

Preventing Recurrent Strokes Needs Improvement One in 12 people who have a stroke will likely soon have another one, and one in four will likely die within one year, according to a new study.

Oxytocin Hormone May Treat Autism Oxytocin — the so-called hormone of love — may help promote social skills and social behavior in people with high-functioning autism, a study shows.

Gluten-Free Camp Helps Celiac Disease Kids A week at a gluten-free camp improves the lives of kids with celiac disease, say researchers at the University of California, San Francisco.

Proteonomix Establishes New Subsidiary Proteonomix has formed a wholly-owned subsidiary, Proteonomix Regenerative Translational Medicine Institute (PRTMI). The new unit is likely to focus on the translation of research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.

Dainippon Sumitomo Declares Second Mid-term Business Plan Dainippon Sumitomo Pharma (Dainippon Sumitomo) has formulated the second mid-term business plan (MTBP) for the five years beginning fiscal 2010.

LCT To Receive NZ $4.04m From New Zealand Government Grant Living Cell Technologies (LCT) to receive a grant of NZ$4.04m from the New Zealand government’s Foundation for Research Science & Technology. The funds from the grant are to be made available over two years to support the ongoing development of Diabecell, LCT’s lead product for [...]

Euthymics Signs LOI To Acquire Dov Pharmaceutical Euthymics Bioscience (Euthymics) has signed a non-binding Letter of Intent (LOI) to merge into and acquire Dov Pharmaceutical for $2m in cash, plus payment of certain of Dov’s expenses. Dov is a biopharmaceutical company focused on the development of novel product candidates for disorders of the central nervous [...]

Bioniche Reaches Additional Milestones In Licensing Agreement With Endo Bioniche Life Sciences (Bioniche) has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals (Endo), for exclusive rights to develop and market Bioniche’s proprietary product for non-muscle-invasive bladder cancer in North America.